Literature DB >> 2373116

Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1.

M D Bain1, P Purkiss, M Jones, P Bingham, T E Stacey, R A Chalmers.   

Abstract

Over an 18-month period serial observations of plasma tyrosine, methionine and urinary tyrosine metabolites were made and compared with urinary succinylacetone excretion in an infant with tyrosinaemia type 1 treated by diet alone. Despite broadly similar profiles there were significant temporal and quantitative differences between each of these metabolic parameters. Only when plasma tyrosine was kept in the low-normal range by strict phenylalanine restriction (10-15 mg phenylalanine/kg body weight) was detectable succinylacetone consistently eliminated from the urine. Urinary succinylacetone is the only measure of metabolite accumulation immediately proximal to the enzyme defect and its routine measurement will allow more effective control of dietary treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373116     DOI: 10.1007/bf02034752

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  8 in total

1.  Liver transplantation in a 23-year-old tyrosinaemia patient: effects on the renal tubular dysfunction.

Authors:  E A Kvittingen; E Jellum; O Stokke; A Flatmark; A Bergan; G Sødal; S Halvorsen; E Schrumpf; E Gjone
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

Review 2.  Tyrosinaemia type I: orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem.

Authors:  F J van Spronsen; R Berger; G P Smit; J B de Klerk; M Duran; C M Bijleveld; H van Faassen; M J Slooff; H S Heymans
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

Review 3.  Changing concepts: liver replacement for hereditary tyrosinemia and hepatoma.

Authors:  T E Starzl; B J Zitelli; B W Shaw; S Iwatsuki; J C Gartner; R D Gordon; J J Malatuck; I J Fox; A H Urbach; D H Van Thiel
Journal:  J Pediatr       Date:  1985-04       Impact factor: 4.406

4.  Biochemical observations on so-called hereditary tyrosinemia.

Authors:  G E Gaull; D K Rassin; G E Solomon; R C Harris; J A Sturman
Journal:  Pediatr Res       Date:  1970-07       Impact factor: 3.756

5.  Dietary treatment of tyrosinemia type I: importance of methionine restriction.

Authors:  K Michals; R Matolon; P W Wong
Journal:  J Am Diet Assoc       Date:  1978-11

6.  The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

Authors:  A G Weinberg; C E Mize; H G Worthen
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

7.  Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.

Authors:  M Tuchman; D K Freese; H L Sharp; C B Whitley; M L Ramnaraine; R A Ulstrom; J S Najarian; N Ascher; N R Buist; A B Terry
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

8.  On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone.

Authors:  S P Fällström; B Lindblad; G Steen
Journal:  Acta Paediatr Scand       Date:  1981
  8 in total
  3 in total

1.  Therapeutic trials in the murine model of hereditary tyrosinaemia type I: a progress report.

Authors:  M Grompe; K Overturf; M al-Dhalimy; M Finegold
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

2.  Clinical features and diagnostic approach in type I tyrosinaemia in an infant with cytomegaly virus infection and bacterial sepsis.

Authors:  M Wabitsch; F Pohlandt; D Leupold; R Berger; E Mönch; E Heinze; W Teller
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

3.  Hereditary tyrosinemia type I-associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate.

Authors:  Iratxe Macias; Ana Laín; Ganeko Bernardo-Seisdedos; David Gil; Esperanza Gonzalez; Juan M Falcon-Perez; Oscar Millet
Journal:  J Biol Chem       Date:  2019-07-12       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.